ALMS Stock Summary and Trading Ideas (Alumis | NASDAQ:ALMS)

Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases.

Alumis trades on the NASDAQ stock market under the symbol ALMS.

As of October 14, 2026, ALMS stock price declined to $6.44 with 166,580 million shares trading.

ALMS has a beta of 0.79, meaning it tends to be less sensitive to market movements. ALMS has a correlation of 0.01 to the broad based SPY ETF.

ALMS has a market cap of $833.56 million. This is considered a Small Cap stock.

Last quarter Alumis reported $2 million in Revenue and -$1.11 earnings per share. This fell short of revenue expectation by $-2 million and missed earnings estimates by -$.40.

The top ETF exchange traded funds that ALMS belongs to (by Net Assets): VTI, VXF, IWM, VTWO, XPH.

ALMS has outperformed the market in the last year with a return of +39.7%, while the SPY ETF gained +17.7%. However, in the most recent history, ALMS shares have underperformed the stock market with its stock returning -77.1% in the last 3 month period and -11.7% for the last 2 week period, while SPY has returned +3.4% and +1.1%, respectively.

ALMS support price is $6.32 and resistance is $6.80 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ALMS shares will trade within this expected range on the day.